Diet changes to improve immune therapy outcomes in melanoma patients
Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma
This study is looking at how eating certain prebiotic foods can help improve gut health and boost the effectiveness of cancer treatments for patients with metastatic melanoma, so you'll get support on how to add these foods to your diet while you continue your regular therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10939497 on NIH RePORTER |
What this research studies
This research investigates how a prebiotic diet can enhance the gut microbiome and improve responses to immune checkpoint inhibitors in patients with metastatic melanoma. By providing specific prebiotic foods and nutritional counseling, the study aims to support beneficial gut microbes that may enhance the immune response during cancer treatment. Patients will be guided on how to implement and maintain this dietary intervention alongside their standard cancer therapies. The approach is based on evidence that gut microbiome profiles can influence treatment outcomes and side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who are receiving immune checkpoint inhibitor therapy.
Not a fit: Patients who are not undergoing immunotherapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment responses and reduced side effects for melanoma patients undergoing immunotherapy.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy responses through dietary interventions, indicating that this approach may be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Daniel-Macdougall, Carrie — University of Tx Md Anderson Can Ctr
- Study coordinator: Daniel-Macdougall, Carrie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.